Compare Stocks: TSHA, HHH, TGTX, and ORKA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HHH Howard Hughes	$68.38 +0.3%	$68.63	$61.01 ▼ $91.07	$4.08B	1.14	440,761 shs	207,911 shs
ORKA Oruka Therapeutics	$105.76 -3.6%	$90.33	$14.10 ▼ $115.51	$7.00B	-0.34	1.13 million shs	351,465 shs
TGTX TG Therapeutics	$50.91 -1.5%	$52.88	$26.76 ▼ $59.30	$7.79B	1.62	2.20 million shs	1.59 million shs
TSHA Taysha Gene Therapies	$5.98 -7.0%	$6.16	$2.71 ▼ $7.30	$1.95B	1.22	2.87 million shs	826,431 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HHH Howard Hughes	+3.55%	+2.43%	-0.56%	+5.64%	-8.36%
ORKA Oruka Therapeutics	-3.00%	+2.13%	+19.61%	+86.90%	+653.37%
TGTX TG Therapeutics	+2.85%	+4.42%	-4.21%	+31.73%	+85.14%
TSHA Taysha Gene Therapies	+3.88%	+0.31%	+15.23%	+16.06%	+126.41%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HHH Howard Hughes	$68.38 +0.3%	$68.63	$61.01 ▼ $91.07	$4.08B	1.14	440,761 shs	207,911 shs
ORKA Oruka Therapeutics	$105.76 -3.6%	$90.33	$14.10 ▼ $115.51	$7.00B	-0.34	1.13 million shs	351,465 shs
TGTX TG Therapeutics	$50.91 -1.5%	$52.88	$26.76 ▼ $59.30	$7.79B	1.62	2.20 million shs	1.59 million shs
TSHA Taysha Gene Therapies	$5.98 -7.0%	$6.16	$2.71 ▼ $7.30	$1.95B	1.22	2.87 million shs	826,431 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HHH Howard Hughes	+3.55%	+2.43%	-0.56%	+5.64%	-8.36%
ORKA Oruka Therapeutics	-3.00%	+2.13%	+19.61%	+86.90%	+653.37%
TGTX TG Therapeutics	+2.85%	+4.42%	-4.21%	+31.73%	+85.14%
TSHA Taysha Gene Therapies	+3.88%	+0.31%	+15.23%	+16.06%	+126.41%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HHH Howard Hughes	1.67	Reduce	$79.00	15.90% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$134.30	22.44% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	21.88% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	98.59% Upside

Current Analyst Ratings Breakdown

Latest TSHA, HHH, TGTX, and ORKA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ORKA Oruka Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$200.00
8/11/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00
8/11/2026	ORKA Oruka Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$151.00
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/6/2026	HHH Howard Hughes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Hold (C-)
8/4/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/3/2026	ORKA Oruka Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
7/29/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
7/27/2026	TGTX TG Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $86.00
7/21/2026	TSHA Taysha Gene Therapies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
7/21/2026	HHH Howard Hughes	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HHH Howard Hughes	$2.37B	1.71	$6.43 per share	10.60	$44.10 per share	1.55
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$16.79 per share	N/A
TGTX TG Therapeutics	$616.29M	12.84	$2.88 per share	17.94	$3.95 per share	13.09
TSHA Taysha Gene Therapies	$9.77M	214.44	N/A	N/A	$1.19 per share	5.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HHH Howard Hughes	$131.88M	$4.94	13.80	22.06	N/A	12.31%	10.19%	2.96%	N/A
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	N/A
TGTX TG Therapeutics	$447.18M	$2.74	18.86	19.51	2.15	55.22%	73.49%	34.14%	11/2/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest TSHA, HHH, TGTX, and ORKA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/5/2026	Q2 2026	HHH Howard Hughes	$0.49	$2.68	+$2.19	$2.68	N/A	$1.12 billion
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HHH Howard Hughes	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HHH Howard Hughes	2.08	1.58	1.58
ORKA Oruka Therapeutics	N/A	38.51	38.51
TGTX TG Therapeutics	1.23	4.27	3.72
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HHH Howard Hughes	93.83%
ORKA Oruka Therapeutics	56.44%
TGTX TG Therapeutics	58.58%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
HHH Howard Hughes	48.00%
ORKA Oruka Therapeutics	23.49%
TGTX TG Therapeutics	8.87%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HHH Howard Hughes	608	59.63 million	31.01 million	Optionable
ORKA Oruka Therapeutics	N/A	66.21 million	50.66 million	N/A
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable
TSHA Taysha Gene Therapies	180	325.83 million	314.50 million	Optionable

TSHA, HHH, TGTX, and ORKA Headlines

Recent News About These Companies

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell?

3 hours ago | marketbeat.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18 at 10:56 PM | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

August 18 at 4:28 AM | marketbeat.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down on Disappointing Earnings

August 14, 2026 | americanbankingnews.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why

August 13, 2026 | marketbeat.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

August 12, 2026 | marketbeat.com

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11, 2026 | marketbeat.com

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) Expected to Post Quarterly Earnings on Tuesday

August 10, 2026 | americanbankingnews.com

Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11

August 4, 2026 | globenewswire.com

Taysha Gene Therapies (TSHA) to Announce Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Taysha Taps Catalent for Potential Commercial Manufacturing of TSHA-102

August 3, 2026 | finance.yahoo.com

Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

August 3, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, TGTX, and ORKA Company Descriptions

Howard Hughes NYSE:HHH

$68.38 +0.18 (+0.26%)

As of 02:04 PM Eastern

Howard Hughes Holdings Inc., together with its subsidiaries, operates as a real estate development company in the United States. It operates in four segments: Operating Assets; Master Planned Communities (MPCs); Seaport; and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multi-family properties along with other retail investments. Its MPCs segment develops, sells, and leases residential and commercial land designated for long-term community development projects in and around Las Vegas, Nevada; Houston, Texas; and Phoenix, Arizona. The Seaport segment is involved in the landlord operations, managed businesses, and events and sponsorships services of its restaurant, retail, and entertain properties in Pier 17, New York City; Historic Area/Uplands; and Tin Building, as well as in 250 Water Street and in the Jean-Georges restaurants. The Strategic Development segment develops and redevelops residential condominiums and commercial properties. It serves homebuilders. Howard Hughes Holdings Inc. was founded in 2010 and is headquartered in The Woodlands, Texas.

Oruka Therapeutics NASDAQ:ORKA

$105.76 -3.93 (-3.58%)

As of 02:03 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

TG Therapeutics NASDAQ:TGTX

$50.91 -0.78 (-1.51%)

As of 02:03 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Taysha Gene Therapies NASDAQ:TSHA

$5.98 -0.45 (-7.00%)

As of 02:04 PM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, TGTX, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, TGTX, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, TGTX, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, TGTX, and ORKA Company Descriptions

Howard Hughes NYSE:HHH

Oruka Therapeutics NASDAQ:ORKA

TG Therapeutics NASDAQ:TGTX

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TSHA, HHH, TGTX, and ORKA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TSHA, HHH, TGTX, and ORKA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TSHA, HHH, TGTX, and ORKA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA, HHH, TGTX, and ORKA Company Descriptions

Howard Hughes NYSE:HHH

Oruka Therapeutics NASDAQ:ORKA

TG Therapeutics NASDAQ:TGTX

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools